2. Cheryl Li - 中英双语版.pdfVIP

美国仿制药市场和仿制药竞争 US MARKET OF GENERIC DRUGS SEPTEMBER 5-6, 2013 CHERYL LI, PH.D. SVP, CMC SERVICES, FRONTAGE LABS CORPORATE OVERVIEW CORPORATE OVERVIEW GENERICS: SIZE OF OPPORTUNITIES • The global Rx generics – $50 billion in 2004 – $80 billion in 2012 • In the US along – $17 billion in 2000 – $51 billion in 2012 • On track to surpass branded drugs in sales value and volumes within a few years • 80 % of all scripts written are for generics • Patent expiry in the US during the next 7 yrs is substantial – 43 small-molecule drugs losing patent protection ($22 billion) in product sales in 2012 – 34 ($13 billion) in 2013 – 40 ($14 billion) in 2014 CORPORATE OVERVIEW We are limited, not by our abilities, but by our vision. K. Gibran 仿制药：巨大的机遇 • The global Rx generics – 2004年达到500亿美金 – 2012年超过800亿美金 • 仅在美国 – 2000年达到170亿美金 – 2012年超过510亿美金 • 几年内将超过品牌药的销售额和销售量 • 80 % of all scripts written are for generics • 众多的专利将在今后的7年内过期 – 2012年，有43个小分子药物(220亿美金销售额）专利 到期 – 2013年，34个小分子药物(130亿美金销售额）专利到 期 – 2014年，40个小分子药物(140亿美金销售额) 专利到 期 CORPORATE OVERVIEW We are limited, not by our abilities, but by our vision. K. Gibran WORLD’S TOP 20 PRODUCTS (12 EXPIRY BY 2016) Rank Pdt/Company 2011 Sales Rank Pdt/Company 2011 Sales (US $ Bn) (US $ Bn) 1 Lipitor (Pfizer) $ 12.5 11 Singular (MSD) $ 6.1 2 Plavix (BMS/Sanofi) $9.3 12 Zyprexa (Lilly) $5.7 3 Seretide (GSK) $8.7 13 Mabthera (Roche) $5.7 4 Crestor (AZ) $8.0